<- Go Home
Medicus Pharma Ltd.
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. Medicus Pharma Ltd. has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was incorporated in 2008 and is headquartered in Conshohocken, Pennsylvania.
Market Cap
$46.9M
Volume
213.1K
Cash and Equivalents
$8.7M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$8.94
52 Week Low
$1.79
Dividend
N/A
Price / Book Value
-49.08
Price / Earnings
-0.92
Price / Tangible Book Value
-49.08
Enterprise Value
$45.4M
Enterprise Value / EBITDA
N/A
Operating Income
-$21.4M
Return on Equity
2660.81%
Return on Assets
-170.69
Cash and Short Term Investments
$8.7M
Debt
$7.1M
Equity
-$804.9K
Revenue
N/A
Unlevered FCF
-$11.4M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium